These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 12776220)
1. Ophthalmic drug discovery. Clark AF; Yorio T Nat Rev Drug Discov; 2003 Jun; 2(6):448-59. PubMed ID: 12776220 [TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
3. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Myles ME; Neumann DM; Hill JM Adv Drug Deliv Rev; 2005 Dec; 57(14):2063-79. PubMed ID: 16310884 [TBL] [Abstract][Full Text] [Related]
4. Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Zhang K; Zhang L; Weinreb RN Nat Rev Drug Discov; 2012 Jun; 11(7):541-59. PubMed ID: 22699774 [TBL] [Abstract][Full Text] [Related]
6. Novel drug delivery systems for retinal diseases. A review. Lee SS; Robinson MR Ophthalmic Res; 2009; 41(3):124-35. PubMed ID: 19321933 [TBL] [Abstract][Full Text] [Related]
7. Advances in glaucoma therapeutics. Clark AF; Pang IH Expert Opin Emerg Drugs; 2002 May; 7(1):141-63. PubMed ID: 15989541 [TBL] [Abstract][Full Text] [Related]
8. Status of therapies in development for the treatment of age-related macular degeneration. Hunt DW; Margaron P IDrugs; 2003 May; 6(5):464-9. PubMed ID: 12789601 [TBL] [Abstract][Full Text] [Related]
9. Microdialysis assessment of drug delivery systems for vitreoretinal targets. Duvvuri S; Rittenhouse KD; Mitra AK Adv Drug Deliv Rev; 2005 Dec; 57(14):2080-91. PubMed ID: 16271800 [TBL] [Abstract][Full Text] [Related]
10. Nanotechnology in ocular drug delivery. Sahoo SK; Dilnawaz F; Krishnakumar S Drug Discov Today; 2008 Feb; 13(3-4):144-51. PubMed ID: 18275912 [TBL] [Abstract][Full Text] [Related]
12. [Age Related Macular Degeneration--a review]. Björnsson OM; Kinge B Laeknabladid; 2005; 91(7-8):591-5. PubMed ID: 16155343 [TBL] [Abstract][Full Text] [Related]
13. Treatment of neovascular age-related macular degeneration: past, present and future directions. Smith BT; Joseph DP; Grand MG Curr Opin Ophthalmol; 2007 May; 18(3):240-4. PubMed ID: 17435433 [TBL] [Abstract][Full Text] [Related]
14. Ophthalmic drug delivery considerations at the cellular level: drug-metabolising enzymes and transporters. Attar M; Shen J; Ling KH; Tang-Liu D Expert Opin Drug Deliv; 2005 Sep; 2(5):891-908. PubMed ID: 16296785 [TBL] [Abstract][Full Text] [Related]
15. HMG CoA reductase inhibitors (statins): do they have a role in age-related macular degeneration? Guymer RH; Chiu AW; Lim L; Baird PN Surv Ophthalmol; 2005; 50(2):194-206. PubMed ID: 15749309 [TBL] [Abstract][Full Text] [Related]
16. Nerve growth factor eye drops to treat glaucoma. Lambiase A; Mantelli F; Bonini S Drug News Perspect; 2010; 23(6):361-7. PubMed ID: 20697603 [TBL] [Abstract][Full Text] [Related]
17. Sustained-release ophthalmic drug delivery systems for treatment of macular disorders: present and future applications. Booth BA; Vidal Denham L; Bouhanik S; Jacob JT; Hill JM Drugs Aging; 2007; 24(7):581-602. PubMed ID: 17658909 [TBL] [Abstract][Full Text] [Related]
19. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Del Amo EM; Urtti A Drug Discov Today; 2008 Feb; 13(3-4):135-43. PubMed ID: 18275911 [TBL] [Abstract][Full Text] [Related]
20. Ocular hypotensive drugs. Willis AM Vet Clin North Am Small Anim Pract; 2004 May; 34(3):755-76. PubMed ID: 15110983 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]